newsfilter
← Latest News
GlobeNewswire·

Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results

Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023 The Company